In this webinar, hosted by DDW and sponsored by Tecan, you will learn about the biggest challenges and opportunities facing the NGS oncology space. 
You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio, and Dr Steve Sheardown Head of Molecular Biology and Cell Engineering at Cerevance. 
Darrell Green will tell a personal story about why he investigates primary bone cancer, shares why commercial kits used for small RNA NGS studies are biased and how to reduce the bias to reveal novel small RNAs, and explains why and how these new small RNAs are investigated at the molecular level, which leads to new drug development.  
Panna Sharma will discuss some of the use-cases of NGS in developing oncology targets and the benefits and challenges we’re seeing in regard to the technology’s use.
Dr Sheardown will discuss Cerevance’s work in producing comprehensive transcriptional profiles of specific brain cell types and how it has used the Trio RNA-Seq Library Preparation Kit with Tecan's DreamPrep NGS automation to generate good data from difficult materials.
NGS has transformed the genomics market from basic research to the clinic, and so Dr Budel and Dr Edwards’ presentation will focus on the pivotal role NGS plays at various developmental stages in biopharma, most notably in oncology.
In this webinar you will learn:
  • How is NGS being used to find new drugs to treat cancer? 
  • Can NGS increase the chances of an oncology drug making it to market?  
  • Can NGS identify previously undruggable targets in cancer?  
  • How can the technology best be implemented in research labs?  
  • Will NGS help drive personalised cancer therapies?
An audience Q&A session with the presenter follows the webinar presentation.

Watch the webinar on-demand now!

Watch the Webinar